592 results about "Low-density lipoprotein" patented technology

A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.

The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.

The present invention relates to materials and methods for the in vivo transport and deliver of nucleic acids. More particularly, it concerns the use of lipoproteins, including but not limited to, low density lipoproteins ("LDL"), and/or apolipoproteins for the binding and in vivo transport of nucleic acids. In addition, the present invention relates to the use of lipoproteins in the early detection of cancer and/or metastatic cancer and/or arteriosclerosis.

The invention provides compositions containing one or more sterol compounds and one or more fatty acid compounds. The invention also provides methods for reducing CVD risk factors such as LDL cholesterol levels.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The present invention provides a non-naturally occurring High-Density Lipoprotein-like peptide-phospholipid scaffold (“HPPS”) nanoparticle. More particularly, the invention provides a non-naturally occurring peptide-lipid nanoscaffold comprising: (a) at least one phospholipid; (b) at least one unsaturated lipid, preferably an unsaturated sterol ester, further preferably an unsaturated cholesterol ester, further preferably cholsteryl oleate; and (c) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; wherein the components a), b) and c) associate to form the peptide-phospholipid nanoscaffold. In embodiments of the present invention, a cell surface receptor ligand is incorporated into the HPPS. In one embodiment, the cell surface receptor ligand is covalently bonded to the peptide scaffold of the HPPS nanoparticles. In other embodiments, a cell surface receptor ligand is coupled to a lipid anchor and is displayed on the surface of the HPPS nanoparticles by incorporation of the lipid anchor into the phospholipids monolayer of the HPPS nanoparticle. The present invention also provides pharmaceutical formulations comprising HPPS nanoparticles and methods of making the HPPS nanoparticles.

A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and/or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

The invention relates to a nutritional blend oil with balanced fatty acid components and active components for the middle and old aged, which is prepared by a plurality of plant oils selected from flaxseed oil, walnut oil, double-low rapeseed oil, soybean oil, wheat germ oil, corn oil, teal oil, peanut oil, grape seed oil, rice bran oil, camellia oil, evening primrose seed oil, sunflower seed oil and the like, wherein, Omega 6 serial polyunsaturated fatty acids (PUFA) and Omega 3 serial PUFA are contained to enable the ratio of saturated fatty acid (SFA) to monounsaturated fatty acid (MUFA) to PUFA to be 0.6-0.8:1:1, the ratio of Omega 6 to Omega 3 to be 4:1 in the comprehensive evaluation of the blend oil absorbed by the middle and old aged and the fat from other sources, thereby meeting the recommended value of Chinese Nutrition Society; the nutritional blend oil contains 2% of gama-linolenic acid, thereby beneficial to improving the contents of DH-gama-linolenic acid and arachidonic acid; the total content of lauric acid, myristic acid and palmitic acid contained in the nutritional blend oil is below 8.5% in order to avoid over rising the level of Low density lipoprotein (LDL) in the plasm of the middle and old aged; in addition, the nutritional blend oil also comprises a plurality of active components with oxidation resistant property, so other antioxidants do not need to be added in the blend oil.The blend oil provided by the invention is characterized by low cost, balanced fatty acid nutrition, a plurality of abundant active components and higher security, thereby better improving the health and intelligence of eaters, preventing cardiovascular and cerebrovascular diseases, and avoiding fatness, hyperlipidemia, thrombotic diseases and the like caused by unbalanced fatty nutrition.

The invention provides an antrodia camphorate cultivation method; firstly, pre-cultivating the antrodia camphorate on a slant culture medium, taking out a part of pre-cultivated antrodia camphorate to inoculate a liquid culture medium, and then inoculating the antrodia camphorate cultivated in the liquid culture medium to a solid culture medium for the cultivation. The antrodia camphorate cultivated in the method has similar effects of wild antrodia camphorate, including effects of restraining growth activity of human cancer cells and cancer auxiliary treatment, also having abilities of restraining human low density lipoprotein oxidation for lowering incidence rates of artery hardening and restoring damaged liver functions.

In the present invention, the markers identified for liver fibrosis and cirrhosis and the microarray panel thereof comprise at least one of the following proteins/genes:

8 up-regulated genes such as

ANXA2; COL1A2; COL3A1; GSN; LDHB; LUM; PDGFRA and TIMP1.

13 down-regulated genes such as

ALB; ANPEP; APOF; AZGP1; BHMT C8A; CFHR4; CFHR5; COL18A1; FTCD; GYS2; ITIH1, and THRAP1.

9 therapeutic targets such as PDGFRA; S100A4; COL3A1; CCL19; DCN; DPT; APP; TNF; and INFG.

The present invention is capable of screening markers for the early warning of the occurrence for severe fibrosis or cirrhosis and potentially targets for drug design.

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

The invention belongs to biology technology field, which concretely refers to controlled release tissue factor path inhibitor (LTFPI) and the manufacturing method, and the application. The invention analyzes and experiments the biology information science and structure molecular biology science of tissue factor path inhibitor (TFPI) and its acceptor low density lipoprotein acceptor correspondent protein (LRP), it ascertains the part where the TFPI carboxy end combines with LRP and is eliminated. It designs TFPI carboxy end mutant, which is recombined with primary nucleus or eukarya expressing carrier after constructing LTFPI gene through PCR location, it converts bacillus coli or bici yeast, sifts the high expression project fungus. The primary project fungus are yeasted and expanded, crushed, then they are centrifugated and collects the inclusion body, purifies the LTFPI through molecular sift and ion interchanging two-step method; the eukarya project fungus are carried on with two-step purifying directly. The half-life are prolonged, it has good pour-depressant function.

Provided is an absorption column for body fluid purification by which the saturated adsorption amount of a substance to be adsorbed can be increased or the time required for reaching the saturated adsorption can be shortened, and therefore, the column capacity can be considerably reduced and the treatment time can be considerably shortened. The adsorption column having functional groups 6 specifically binding to a substance to be adsorbed including at least low density lipoprotein, immobilized on the surface of a porous support 5. The porous support 5 has double-pore structure comprising: a skeleton 7 made of a silica gel or silica glass having a three-dimensional network structure; through-pores 8 of an average diameter measured by the mercury intrusion method of 1 μm or more but less than 4 μm and having a three-dimensional network structure, which are formed in the voids of the skeleton; and micropores 9 having an average diameter measured by the mercury intrusion method larger than the grain diameter of the substance to be adsorbed, which are dispersedly formed on the surface of the skeleton.

The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.

A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol and/or lean body mass in humans and animals. The method comprises administering policosanol and chromium and/or chromium salts which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and/or chromium salts.

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1_c, lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

A composition containing EPA and EHA, preferably derived from fish oil, in combination with at least one of oleuropein, allicin, and policosanol having anti-inflammatory, anti-thrombotic, immunomodulatory activity as well as activity to lower triglycerides and low density lipoprotein, to increase high density lipoprotein, and to lower both systolic and diastolic blood pressure.

This disclosure relates to a low density lipoprotein-like cationic solid lipid nanoparticle targeting liver cells including parenchyma cells and non-parenchyma cells, a composition for liver target delivery, a composition for diagnosis and/or treatment of liver disease comprising the same, and a method for liver targeting of an active ingredient.